Two abstracts related to Desentum’s product development projects have been accepted for presentation at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Türkiye, on Jun 12–15, 2026. The abstracts focus on the development of methods and models important for ensuring the quality and reliability of preclinical and clinical study results.
In a Flash Talk session, a humanized mouse model developed for peanut allergy will be presented. The model has been used in the preclinical validation of Desentum’s product candidate for immunotherapeutic treatment of peanut allergy.
In a poster session, the nasal allergen challenge used for assessing symptoms in the Phase II clinical study of the investigational birch pollen AIT product DM-101PX will be presented.
The details of the presentations are:
Saturday 13 June 2026 at 12:00–13:00, Thematic Poster Session 39 – Allergen immunotherapy 03
Evaluation of a commercially available Birch Pollen Extract for its suitability in Nasal Allergen Challenges: Feasibility and Dose-Response Assessment
Presenter: Saba Haider, Cliantha Research Ltd, Canada
Sunday 14 June 2026 at 15:15–16:45, Flash Talk 21 – Mechanistic insight in AIT
Dose-dependent anaphylaxis induced by subcutaneously administered Ara h 2 in a humanized mouse model for peanut allergy
Presenter: Dr Kirsi Hellström, Desentum Oy, Finland
About Desentum
Desentum Oy is a clinical-stage biopharmaceutical company based in Espoo, Finland, leveraging high-resolution protein engineering and drug delivery technologies for designing allergy vaccines that enable short-course treatment to restore long-term tolerance. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd. With its product development, Desentum targets both respiratory and food allergies.